BioNotebook: IPOs, pipeline progress amidst bubble talk
This article was originally published in Scrip
Executive Summary
Recro prices and Akebia, Ignyta set IPO terms; NewLink, Northwest studies continue; Alkermes, Regulus start trials; Theravance split-up progresses; Teva launches Alexza's Adasuve; and Cumberland acquires Astellas drug.